The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Validation, 2011Pre-clinical Models Specifying Nicotinic Receptor Targets in Parkinson's Disease Neuroprotection
Objective/Rationale:
The scientific community has known since 1959 that tobacco use has apparent protective effects against Parkinson’s disease (PD), and some animal models suggest that this... -
Dyskinesia, 2011Targeting Serotonin Transporters for the Treatment of L-DOPA-induced Dyskinesia
Objective/Rationale:
Levodopa remains the gold-standard treatment for Parkinson’s disease, unfortunately chronic treatment leads to abnormal involuntary movements known as dyskinesia. In recent years... -
Biomarkers, 2011Identifying Peripheral Inflammatory Markers for Parkinson's Disease with Dementia (PDD)
Objective/Rationale:
Patients with Parkinson’s disease (PD) are at a 5.9 times greater risk of developing dementia than the normal population. The identification of sensitive molecular and cellular... -
Rapid Response Innovation Awards, 2011Effect of Deep Brain Stimulation on Cortical Cross Frequency Coupling in Parkinson's Disease: An Electrocorticography Study
Objective/Rationale:
Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is a common treatment for Parkinson’s disease (PD). Much research has focused on the effects of DBS on the STN and... -
Therapeutics Development Initiative, 2011Next Generation Parkinson's Disease Treatment through Steering Brain Stimulation (NEXT)
Objective/Rationale:
Deep Brain Stimulation (DBS) can provide a radical improvement in the quality of life of Parkinson’s patients. However, it is a complex procedure with a large incidence of... -
Therapeutics Development Initiative, 2011Characterization of NPT001-mediated Alpha-Synuclein Disaggregation and Clearance
Objective/Rationale:
Abnormal accumulation of alpha-synuclein in the brain is associated with toxicity and disease progression in Parkinson’s and other neurodegenerative diseases. NPT001 has been...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.